For clinicians & researchers
Interested in advising or partnering?
We're actively building our clinical network and scientific advisory board.
Ovealth brings together translational drug development expertise, reproductive medicine, and commercial operations — the intersection where this field has needed a company to be built.
The science isn't the problem. The delivery is. For twenty years, the evidence has outpaced the infrastructure — Ovealth is the first company built to match.
Ovealth was founded by Sehresh Saleem, PhD — a geneticist and biotech program manager with over a decade leading therapeutic programs at Sangamo Therapeutics, CytomX, and NeoGenomics. After watching the field of ovarian tissue preservation remain trapped inside academic medical centers despite decades of evidence, she left drug development to build the modern infrastructure that ovarian biology deserves.
Her work spans antibody therapeutics from discovery through IND, Phase 1 oncology and rare disease operations, and deep program management in environments where clinical rigor and regulatory precision are non-negotiable. That operating background now applies to a category that has been scientifically solved for years but organizationally underbuilt.
We're actively building our clinical network and scientific advisory board.
See how ovarian tissue preservation works, who it's for, and how to begin a conversation with us.
Return to Ovealth →